Pharma & Bio
Lifestyle
U.S.-Based Biotech Company Sets to Become a Successful KOSDAQ Listing [In-Depth Look at Ingenia, Part 1]
Ingenia Therapeutics (Ingenia), an innovative antibody drug development company headquartered in Boston, U.S., has passed the Korea Exchange’s preliminary review for a KOSDAQ listing and is now moving…
Lifestyle
Choi Seok-geun, CEO of EyeGene,Inc: “The Nation’s Only Combination of mRNA and GCT Technologies Will Accelerate the Path to a ‘Profitable Biotech Company’”
"We will break free from the limitations of a biotech venture that remains confined to research and development (R&D). By progressively commercializing our proven revenue-generating pipeline—including…
Lifestyle
Patient Monitoring Market: A Silent Battle... SEERS’ Strategy to Expand into Neurology
As competition in the domestic patient monitoring market intensifies, SEERS TECHNOLOGY(458870)is seeking to differentiate itself by expanding its market presence based on clinical data. Rather than en…
Technology
Hyundai pharm Rises with Every Presidential Remark… Beyond Policy Themes, Earnings and Structural Improvements Are Accelerating
Hyundai pharm(004310)The company has been drawing market attention every time the Lee Jae-myung administration makes statements regarding pharmaceutical policy. Following a sharp rise in its stock pri…
Technology
[K-Bio Pulse] Biotech Stocks Defy 'Black Tuesday' as MedPacto Soars, Bioinfra Faces Deadline
Despite the “Black Tuesday” sell-off on July 28, several biotech stocks bucked the broader market trend. As the KOSDAQ tumbled, Cellid, Bioinfra, and MedPacto all hit the daily upper limit. MedPacto g…
Technology
[Bio Spotlight] Biotech Stocks Rebound After 'Black Tuesday'… MedPacto, Inc. Rises, Two Days That Will Decide BioInfra Co.,Ltd.’s Fate
On the 28th, dubbed “Black Tuesday,” some biotech stocks hit their daily price limit. On a day when the KOSDAQ market plummeted, Cellid Co., Ltd.(299660), BioInfra Co.,Ltd.(199730), and MedPacto, Inc.…
Lifestyle
[Exclusive] Ingenia Puts New Kidney Drug on the Table for Technology Export... Hints at a “Trillion-Won” Mega Deal
Ingenia Therapeutics (Ingenia), an innovative antibody drug developer set to list on KOSDAQ, has brought a treatment for chronic kidney disease (CKD) to the negotiating table with a global big pharma …
Lifestyle
Biotech Startups’ Risky Moves… Why the “Build First, Then Lease” Formula Persists
There have been repeated instances of domestic biotech startups building factories even before product development is complete or before signing contracts with global companies. However, contrary to e…
Technology
Park Young-kyu, CEO of BRP Connect: "Pharmaceutical Data Is Our Weapon… We Will Build a Homegrown Platform That Surpasses IQVIA"
South Korea’s pharmaceutical and biotech industry is entering an era of “data competition.” A company’s ability to respond to market dynamics hinges on how quickly and accurately it can analyze trends…
Technology
i-SENS Soars on Earnings, Peptron Rebounds, Cellid Hits Limit-Up [K-Bio Pulse]
South Korean pharmaceutical and biotechnology stocks were mixed on Monday, with i-SENS soaring after reporting second-quarter earnings that far exceeded market expectations, Peptron extending its rebo…